FDA 483 - American Red Cross National Headquarters - December 20, 2002

A recent FDA inspection in 2002, following up on issues identified in 2000, found numerous and significant objectionable conditions at ARC's Biomedical Headquarters (BHQ) related to the manufacturing and distribution of blood products. The main violations included a systemic failure to adequately investigate employee allegations of record falsification and non-concurrent documentation, often dismissing them as isolated instances despite recurring reports. The inspection also revealed critical deficiencies in managing donor deferral processes, including inadequate investigations of potential problems with deferral rates and incomplete investigations of suspected post-transfusion hepatitis cases, failing to identify implicated donors or trace affected products. Furthermore, BHQ's inventory and distribution systems were found to be severely lacking, resulting in the inability to track thousands of blood products, leading to the reissuance and transfusion of unsuitable or recalled units. This issue was a repeat observation from a prior inspection. Additional concerns involved inadequate oversight of regional inventory management, failure to establish proper procedures for frozen red blood cell inventory, and persistent errors in CMV labeling of blood components, another recurring problem that led to the release and transfusion of incorrectly labeled products. Critically, the National Donor Deferral Registry (NDDR) was found to be inaccurate and incomplete, missing records for thousands of permanently deferred high-risk donors due to procedural flaws, software defects, and insufficient training, directly jeopardizing patient safety. These findings indicate a pervasive failure to implement effective corrective and preventive actions, with many issues being long-standing or recurring, underscoring the urgent need for comprehensive remediation to ensure compliance with regulatory standards and safeguard public health.